Recursion Authorizes Substantial Equity Awards to Drive Recruitment Strategy

Recursion, the clinical-stage biotech company (NASDAQ: RXRX), has revealed details of a significant equity compensation initiative aimed at attracting top talent. The company’s Compensation Committee authorized the distribution of 820,431 restricted stock units (RSUs) covering its class A common stock to 17 newly hired employees in early February 2026. These equity grants were structured as recruitment incentives, issued under the company’s 2024 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635©(4), which governs such non-employee inducement arrangements.

Understanding the RSU Vesting Framework

The inducement RSUs awarded by Recursion follow a staggered vesting schedule designed to encourage long-term employee retention. Under the plan structure, recipients will see 25% of their RSU shares vest on the first quarterly vesting anniversary following one year of employment. The remaining shares will subsequently vest in equal quarterly installments at 1/16th per quarter, contingent upon the employee maintaining their position with Recursion or one of its subsidiaries throughout each vesting period. This multi-year vesting approach is standard industry practice for equity incentives, aligning employee interests with company performance and durability.

Recursion’s Platform Innovation and Global Footprint

Recursion operates at the intersection of advanced technology and biological research, leveraging what the company terms the Recursion OS—a sophisticated computational and experimental platform. This infrastructure continuously generates one of the world’s most extensive proprietary datasets of biological and chemical relationships. The company employs machine-learning algorithms to identify previously undiscovered connections across millions of data points, substantially reducing human bias in research discovery.

Recursion maintains an impressive operational scale, conducting millions of laboratory experiments weekly while operating one of the most powerful supercomputers globally. The company is headquartered in Salt Lake City, Utah, where it serves as a founding member of BioHive, a collaborative initiative supporting the state’s life sciences ecosystem. Recursion has expanded internationally with offices in Montréal, New York, London, and the Oxford area, reflecting its commitment to attracting world-class talent and advancing biotechnology research on a global scale.